Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 3-3 ◽  
Author(s):  
Mathias J. Rummel ◽  
Norbert Niederle ◽  
Georg Maschmeyer ◽  
Andre G. Banat ◽  
Ulrich von Gruenhagen ◽  
...  
Keyword(s):  
Annual Meeting ◽  
Clinical Oncology ◽  
Line Treatment ◽  
First Line ◽  
Daily News ◽  
Online Supplement ◽  
Mantle Cell ◽  
Final Text ◽  
First Line Treatment

3 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Sunday, June 3, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.

Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3).

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. LBA3506-LBA3506
Author(s):  
Volker Heinemann ◽  
Ludwig Fischer von Weikersthal ◽  
Thomas Decker ◽  
Alexander Kiani ◽  
Ursula Vehling-Kaiser ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Line Treatment ◽  
First Line ◽  
Daily News ◽  
Online Supplement ◽  
Final Text ◽  
First Line Treatment

LBA3506 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Saturday June, 1, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.

Phase III trial of a 3-weekly versus 5-weekly schedule of S-1 plus cisplatin (SP) combination chemotherapy for first-line treatment of advanced gastric cancer (AGC): SOS study.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. LBA4024-LBA4024
Author(s):  
Min-Hee Ryu ◽  
Eishi Baba ◽  
Kyung Hee Lee ◽  
Narikazu Boku ◽  
Young Iee Park ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Phase Iii ◽  
Weekly Schedule ◽  
Line Treatment ◽  
First Line ◽  
Daily News ◽  
Phase Iii Trial ◽  
Online Supplement ◽  
Final Text ◽  
First Line Treatment

LBA4024 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Monday, June, 3, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: A GCIG and EORTC-GCG study.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. LBA5000-LBA5000
Author(s):  
Ignace B. Vergote ◽  
Florence Joly ◽  
Dionyssios Katsaros ◽  
Corneel Coens ◽  
Alexander Reinthaller ◽  
...  
Keyword(s):  
Ovarian Carcinoma ◽  
Disease Progression ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Phase Iii ◽  
First Line ◽  
Daily News ◽  
Online Supplement ◽  
Phase Iii Study ◽  
Final Text

LBA5000 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Saturday, June 2, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.

A randomized, phase III study (AGO-OVAR-9, GINECO-TCG, NSGO-OC-0102): Gemcitabine-paclitaxel-carboplatin versus paclitaxel-carboplatin as first-line treatment of ovarian cancer (OC): Survival of FIGO stage I-IIA patients

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. LBA5510-LBA5510
Author(s):  
J. Herrstedt ◽  
J. Huober ◽  
F. Priou ◽  
H. Müller ◽  
M. Baekelandt ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Figo Stage ◽  
Phase Iii ◽  
Line Treatment ◽  
First Line ◽  
Phase Iii Study ◽  
Final Text ◽  
First Line Treatment

LBA5510 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. [Table: see text]

New insights into the risk of breast cancer in childhood cancer survivors treated with chest radiation: A report from the Childhood Cancer Survivor Study (CCSS) and the Women's Environmental Cancer and Radiation Epidemiology(WECARE) Study.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. CRA9513-CRA9513
Author(s):  
Chaya S. Moskowitz ◽  
Joanne F. Chou ◽  
Suzanne L. Wolden ◽  
Jonine L. Bernstein ◽  
Jyoti Malhotra ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Childhood Cancer ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Childhood Cancer Survivors ◽  
Daily News ◽  
Online Supplement ◽  
Radiation Epidemiology ◽  
Childhood Cancer Survivor Study ◽  
Final Text

CRA9513 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Monday, June 4, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study).

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. CRA3503-CRA3503 ◽  
Author(s):  
Dirk Arnold ◽  
Thierry Andre ◽  
Jaafar Bennouna ◽  
Javier Sastre ◽  
Pia J. Osterlund ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Phase Iii ◽  
Daily News ◽  
Online Supplement ◽  
Previously Treated ◽  
Final Text

CRA3503 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Sunday, June 3, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.

Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. LBA506-LBA506 ◽  
Author(s):  
Andre Robidoux ◽  
Gong Tang ◽  
Priya Rastogi ◽  
Charles E. Geyer ◽  
Catherine A. Azar ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Therapy ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Operable Breast Cancer ◽  
Daily News ◽  
Online Supplement ◽  
B 41 ◽  
Final Text

LBA506 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Sunday, June 3, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.

AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC).

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. LBA5002-LBA5002 ◽  
Author(s):  
Eric Pujade-Lauraine ◽  
Felix Hilpert ◽  
Béatrice Weber ◽  
Alexander Reuss ◽  
Andres Poveda ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Recurrent Ovarian Cancer ◽  
Phase Iii ◽  
Daily News ◽  
Phase Iii Trial ◽  
Online Supplement ◽  
Final Text

LBA5002^ The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Saturday, June 2, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.

Correlation of molecular alterations with efficacy of everolimus in hormone-receptor–positive (HR+), HER2-negative advanced breast cancer: Preliminary results from BOLERO-2.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. LBA509-LBA509
Author(s):  
Gabriel N. Hortobagyi ◽  
Martine J. Piccart-Gebhart ◽  
Hope S. Rugo ◽  
Howard A. Burris ◽  
Mario Campone ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Hormone Receptor ◽  
Daily News ◽  
Online Supplement ◽  
Molecular Alterations ◽  
Hormone Receptor Positive ◽  
Final Text

LBA509 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Monday, June, 3, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

Bevacizumab, irinotecan, and radiotherapy versus standard temozolomide and radiotherapy in newly diagnosed, MGMT-non-methylated glioblastoma patients: First results from the randomized multicenter GLARIUS trial.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. LBA2000-LBA2000
Author(s):  
Ulrich Herrlinger ◽  
Niklas Schaefer ◽  
Joachim Peter Steinbach ◽  
Astrid Weyerbrock ◽  
Peter Hau ◽  
...  
Keyword(s):  
Annual Meeting ◽  
Clinical Oncology ◽  
Newly Diagnosed ◽  
Daily News ◽  
Online Supplement ◽  
First Results ◽  
Final Text

LBA2000 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Saturday, June, 1, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.

Sign in / Sign up

Export Citation Format

Share Document